Retaining the C-terminal ethyl ester through solution-phase fragment coupling: reagent ratios and temperature limits

N-(tert-butoxycarbonyl)-L-tyrosine ethyl ester (Boc-Tyr-OEt) is handled as a pre-activated amino acid in liquid-phase convergent syntheses of tyrosine-containing oligopeptide APIs. The ethyl ester protects the carboxyl terminus against rearrangement and base-catalysed oxazolone formation during carbodiimide-mediated coupling, while the Boc group masks the nucleophilic amine. In a typical carbodiimide coupling, Boc-Tyr-OEt is dissolved in anhydrous dichloromethane or dimethylformamide at 0–5°C with 1.05 equivalents of the carboxyl-component peptide acid, 1.10 equivalents of 1-hydroxybenzotriazole hydrate, and 1.10 equivalents of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride. N-methylmorpholine is added slowly to maintain a slightly alkaline environment as judged by spotting on dampened pH paper; the mixture is stirred at 0°C for 1 h and then at 20–25°C for 12–18 h. Methanol and ethanol are excluded from the solvent system because ethyl ester transesterification in alcoholic media reduces yield. The unprotected phenol of tyrosine is not extensively ionised under these coupling conditions, but slow O-acylation can occur with active esters; 1-hydroxybenzotriazole at a 1.0:1.0 ratio to the carbodiimide suppresses O-acylisourea-derived acylation and limits racemization.

Work-up uses ethyl acetate extraction against ice-cold 0.5 M citric acid, saturated sodium bicarbonate and brine. The organic layer is dried over sodium sulfate and concentrated below 40°C. The ethyl ester is retained until final C-terminal deprotection with 1 M lithium hydroxide in tetrahydrofuran/water 1:1 at 0–5°C for 1–2 h. Process developers monitor ester hydrolysis by reverse-phase HPLC on a C18 column with a 0.1% trifluoroacetic acid/acetonitrile gradient; hydrolysis is quenched with solid citric acid before ethyl acetate extraction. Extended alkaline exposure beyond 2 h or temperature above 10°C increases D-enantiomer content through alpha-carbon deprotonation. A chiral HPLC method using an amylose tris(3,5-dimethylphenylcarbamate) column and n-hexane/ethanol/trifluoroacetic acid 90:10:0.1 at 1.0 mL/min verifies enantiopurity. Acceptance criteria for the resulting peptide raw material typically include 0.10% D-Tyr epimer and 0.15% total unidentified organics, aligned with ICH Q3A(R2) identification and qualification thresholds for a maximum daily dose below 2 g/day. The terminal products are tyrosine-containing oligopeptide APIs and their protected fragments.

At the cGMP interface between raw material and API starting material, Boc-Tyr-OEt is typically released against a specification that includes appearance, specific rotation, residual solvents, moisture and chromatographic purity. The material is a white to off-white powder; the certificate of analysis reports specific rotation measured by polarimetry according to USP <781> with the acceptance range defined by the vendor and qualified during process validation. Storage at -20°C under nitrogen in high-density polyethylene drums with silica gel desiccant reduces hydrolysis of the Boc group and ester functions. Incoming QC uses headspace gas chromatography for residual dichloromethane and ethyl acetate, with limits aligned to USP <467>: dichloromethane 600 ppm and ethyl acetate 5000 ppm. Chiral purity is measured on a polysaccharide-based chiral column with an area normalisation threshold of 0.50% for the D-enantiomer; for later API registration the impurity profile is further evaluated against ICH Q3A(R2) thresholds of 0.05% reporting, 0.10% identification and 0.15% qualification. Residual moisture is kept below 0.5% by Karl Fischer titration, and re-test data are typically generated every 12 months. The terminal product of this application is a controlled raw material ready for use as a registered building block in compliant peptide API synthesis; no additional purification is performed before charging into a manufacturing batch.

Can immobilized Candida antarctica lipase B be used to probe enantioselectivity of the ethyl ester substrate?

For enzymatic process development, Boc-Tyr-OEt is used as a model substrate in screening panels because the Boc group and ethyl ester are stable under non-aqueous lipase conditions, while the ester cleavage product N-Boc-L-tyrosine has a distinct retention time. In a typical screen, enantiopure or racemic Boc-Tyr-OEt is suspended at 50 mM in 0.1 M potassium phosphate buffer pH 7.0 containing 10% v/v acetonitrile as co-solvent. Immobilised lipase B from Candida antarctica on acrylic polymer resin, supplied as a commercial immobilised enzyme with approximately 10,000 PLU/g, is added at 10% w/w relative to substrate. The slurry is shaken at 30°C for 24 h; aliquots are quenched with an equal volume of acetonitrile containing 0.1% trifluoroacetic acid, and conversion is calculated by HPLC area percent of the free acid. This reaction is useful for screening enzyme lots, substrate enantiopurity and process robustness rather than as a preparative enzymatic resolution route, because the L-enantiomer is already the desired configuration and the ester hydrolysis product must be re-esterified if the ethyl ester is required again. Published data for this specific substrate-enzyme pair remain limited; the design above is based on standard lipase activity assay configurations for N-protected amino acid esters and is not a validated preparative method. The terminal output is a process-development dataset identifying enzyme lots and substrate quality suitable for downstream peptide intermediate hydrolysis steps.

When only the N-terminal masking group is to be removed while the C-terminal ethyl ester remains intact, acidolysis is carried out with trifluoroacetic acid in anhydrous dichloromethane. Boc removal from Boc-Tyr-OEt requires careful solvent selection because the ethyl ester can undergo acid-catalysed hydrolysis if water is not controlled. A typical bench-scale deprotection uses trifluoroacetic acid and dichloromethane 1:1 v/v at 0–5°C under nitrogen for 60–90 min. The liberated tert-butyl cation is trapped with triisopropylsilane at 2–5% v/v or anisole at 5% v/v; triisopropylsilane is preferred when subsequent evaporation must leave a residue that can be crystallised as a salt. After evaporation below 30°C, the residue is triturated with cold diethyl ether to remove silyl adducts. The product H-Tyr-OEt trifluoroacetate is obtained as an off-white solid. The salt is stored under inert gas; the neutralised free amine is generated in situ with N-methylmorpholine immediately before the next acylation step to avoid aminolysis of the ethyl ester by another molecule of free amine. Residual trifluoroacetic acid in the isolated salt is assayed by ¹⁹F NMR or ion chromatography and is specified below 0.1% w/w when the building block is used in late-stage peptide fragment coupling. The terminal product is H-Tyr-OEt trifluoroacetate, a C-terminal protected amino acid salt used directly in subsequent peptide chain extension.

Side-chain phenol handling during carbodiimide-mediated couplings

Because BOC-L-tyrosine ethyl ester is routinely supplied with the phenolic hydroxyl unprotected, O-acylation can compete with the desired N-acylation under carbodiimide activation. The side-chain phenol pKa is approximately 10.1; at pH 7.5–8.5 only a small fraction is ionised, so O-acylation is slower than amine acylation but not negligible over 12–18 h reaction times. The O-acylisourea route is suppressed by using 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole at 1.0–1.2 equivalents relative to carbodiimide and by adding the activated acid to the amine component at 0–4°C. A common process adjustment is to use N,N′-diisopropylcarbodiimide and ethyl cyanohydroxyiminoacetate at 0.90–0.95 equivalents relative to the carboxylic acid in acetonitrile or dimethylformamide; this combination gives less O-acylation than EDC-derived O-acylisourea and suppresses racemization. If a highly hindered acid does not couple completely, the hydroxyl is temporarily silylated with tert-butyldimethylsilyl chloride and imidazole in dimethylformamide, but fluoride-mediated removal of the silyl group can cleave the ethyl ester; this option is reserved for cases where O-acylation exceeds 2.0 area% by HPLC. Process chemists monitor O-acylation by TLC using ethyl acetate/hexane 1:1; the O-acylated impurity migrates above the N-acylated product and is confirmed by HPLC-MS with an [M+H]+ ion 18 u higher than the N-acylated product. The terminal product of this segment is an N-acylated tyrosine-containing intermediate with controlled O-acyl impurity for continued peptide assembly.

Alkaline ester hydrolysis adjacent to a chiral centre: base selection, temperature and racemization risk

When C-terminal ethyl ester deprotection is required after peptide chain assembly, the tyrosine-containing substrate is treated with alkali in aqueous organic media. Lithium hydroxide is preferred over sodium hydroxide in tetrahydrofuran/water systems because the lithium cation forms a tighter ion pair with the carboxylate intermediate and gives cleaner hydrolysis of the terminal ethyl ester with less beta-elimination of the phenolic side chain. A typical deprotection uses 1.05–1.20 equivalents of 1 M lithium hydroxide in a 1:1 mixture of tetrahydrofuran and water at 0°C to +5°C for 45–120 min. The mixture is quenched with 0.5 M citric acid to pH 3–4 and extracted with cold ethyl acetate. Under these conditions ethyl ester cleavage proceeds without significant Boc loss, because the Boc group is stable to cold dilute aqueous base; however, deprotonation at the alpha carbon is a competing racemization route. The half-life for racemization is strongly temperature dependent; maintaining the hydrolysis below +5°C is critical for peptides with N-terminal ureido or amide groups that increase alpha-proton acidity. Process monitoring uses a chiral HPLC method with an immobilised amylose column and a mobile phase of n-hexane/ethanol/trifluoroacetic acid 90:10:0.1; enantiomer resolution is typically greater than 1.5 between L- and D-tyrosine derivatives. If the D-enantiomer exceeds 0.10% at reaction completion, the batch is rejected or reworked only when a recrystallization has been demonstrated to purge the epimer under quality agreement. The terminal product is the C-terminal free acid peptide fragment ready for the next coupling step or final salt formation.